Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, Kilitch Drugs (India) has informed that the Board of Directors of the Company at its meeting held today i.e., Saturday, 22nd July, 2023 considered and approved the following; Obtaining credit facilities from bank not exceeding Rs 50,50,00,000 for the purpose of meeting day to day fund requirements of the Company. Conversion of 5,00,000 convertible warrants into 5,00,000 equity shares of face value of Rs 10 each of the Company out of the warrants allotted on 24th January, 2023 on preferential allotment basis to the allottees pursuant to exercise of their rights of conversion of warrants into equity shares and accordingly the Board of Directors have allotted 5,00,000 equity shares of face value of Rs 10 each fully paid up on account of conversion.
The above information is a part of company’s filings submitted to BSE.